AR and prostate carcinoma: Table 3 shows how many clinical trials are ongoing and have been conducted using ARV-471. They are targeted against androgen receptors for the treatment of prostate cancer and oestrogen receptors for the treatment of breast cancer. The data comes from the clinical trial registry (clinicaltrials.gov) [42].